{"entity":{"id":"nct05383482","kind":"trial","name":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1","aka":[],"tldr":"A phase 1/2 trial of Afuresertib run by Laekna Limited, completed.","summary":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 is a phase 1/2 interventional study registered as NCT05383482 by Laekna Limited, with 22 participants enrolled, started 2022-07-01, primary completion reached 2024-06-25. Conditions recorded: Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma. Interventions recorded: Afuresertib, Nab paclitaxel, Docetaxel, Sintilimab.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05383482","url":"https://clinicaltrials.gov/study/NCT05383482"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["afuresertib"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05383482","phase":"1/2","setting":"A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment","sponsor":"Laekna Limited","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05383482/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"afuresertib","kind":"drug","name":"Afuresertib","route":"/drugs/afuresertib/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}